| Literature DB >> 32070217 |
Sushena Reza-Paul1,2, Lisa Lazarus1, Raviprakash Maiya2, Partha Haldar3, B B Rewari4, M S Venugopal2, Syed Hafeez Ur Rahman2, K T Venukumar2, Manjula Ramaiah2, Akram Pasha2, Mukta Sharma4, Richard Steen5, Robert Lorway1.
Abstract
To inform PrEP roll out, Ashodaya Samithi, a sex workers' collective, conducted a community-led prospective demonstration project among female sex workers in Mysore and Mandya, India. Following a community preparedness phase and pre-screening, participants were recruited for clinical screening and enrolment, provided PrEP as part of combination HIV prevention, and followed for 16 months. Adherence was measured by self-reported pill intake and by tenofovir blood level testing among a subset of participants. Of the 647 participants enrolled, 640 completed follow-up. Condom use remained stable and no HIV seroconversions occurred. Self-reported daily PrEP intake over the last month was 97.97% at the end of the study. Tenofovir blood levels >40 ng/mL (consistent with steady state dosing) were detected among 80% (n = 68/85) and 90.48% (n = 76/84) of participants at month 3 and 6, respectively. Our study holds important insights for rolling out PrEP in community settings as part of targeted HIV prevention interventions.Entities:
Keywords: HIV prevention; PrEP; community-led; demonstration project; sex work
Year: 2020 PMID: 32070217 PMCID: PMC7261403 DOI: 10.1080/17441692.2020.1724316
Source DB: PubMed Journal: Glob Public Health ISSN: 1744-1692
Figure 1.PrEP flow chart.
Socio-demographic characteristics.
| Characteristic | N (%) |
|---|---|
| N (all participants) | 647 |
| Median (range) | 35 (18–48) |
| <=20 | 5 (0.77) |
| 21–25 | 43 (6.65) |
| 26–30 | 150 (23.18) |
| 31–35 | 151 (23.34) |
| >35 | 298 (46.06) |
| Median (range) | 28 (15–44) |
| <=20 | 73 (11.28) |
| 21–25 | 162 (25.04) |
| 26–30 | 195 (30.14) |
| 31–35 | 131 (20.25) |
| >35 | 86 (13.29) |
| Median (range) | 6 (1–30) |
| <=5 | 309 (47.76) |
| 6–10 | 242 (37.4) |
| 11–15 | 61 (9.43) |
| >15 | 35 (5.41) |
| Illiterate | 379 (58.58) |
| Literate | 268 (41.42) |
| Never married | 15 (2.32) |
| Married | 333 (51.47) |
| Widow/divorced/separated | 299 (46.21) |
| Median (range) | 5400 (2000–30000) |
| <=5000 | 322 (49.77) |
| >5000 | 325 (50.23) |
| Median (range) | 2 (0–6) |
| 0 child | 43 (6.65) |
| 1–2 children | 491 (75.89) |
| >2 children | 113 (17.47) |
Follow-up visits and side effects.
| Follow-up visit | Participants visited for follow-up ( | Participants experienced side effect n (%) |
|---|---|---|
| End of 1st month | 637 (98.5%) | 194 (30.46%) |
| End of 3rd month | 642 (99.23%) | 68 (10.59%) |
| End of 6th month | 641 (99.07%) | 38 (5.93%) |
| End of 9th month | 641 (99.07%) | 11 (1.72%) |
| End of 12th month | 640 (98.98%) | 0 (0%) |
| End of 15th month | 640 (98.92%) | 0 (0%) |
Clinical tests at follow-up visits.
| Characteristic | End of 1st month | End of 3rd month | End of 6th month | End of 9th month | End of 12th month | End of 15th month (exit visit) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | n(%) | N | n(%) | N | n(%) | N | n(%) | N | n(%) | N | n(%) | |
| STI screening | 637 | 1 (0.16) | 642 | 5 (0.78) | 641 | 2 (0.31) | 641 | 0 (0) | 640 | 0 (0) | 640 | 0 (0) |
| HIV test –positive | 637 | 0 (0) | 642 | 0 (0) | 641 | 0 (0) | 641 | 0 (0) | 640 | 0 (0) | 640 | 0 (0) |
| Pregnancy Test- positive | 637 | 0 (0) | 642 | 2 (0.31) | 641 | 0 (0) | 641 | 1 (0.16) | 640 | 0 (0) | 640 | 0 (0) |
| Syphilis-reactive* | 637 | NA | 642 | NA | 641 | 0 (0) | 641 | NA | 640 | 0 (0) | 640 | NA |
| Cervical cancer screening-reactive* | 637 | NA | 642 | NA | 641 | 0 (0) | 641 | NA | 640 | 0 (0) | 640 | NA |
| Kidney function (high serum creatinine clearance) | 637 | 0 (0) | 642 | 0 (0) | 641 | 0 (0) | 641 | 0 (0) | 640 | 0 (0) | 640 | 0 (0) |
*Syphillis and cervical cancer screening are done every six months.
Condom use during last sex with clients and partners during last week.
| Visit | Condom use with occasional clients (%) | Condom use with repeat clients (%) | Condom use with Regular partners (%) | |
|---|---|---|---|---|
| Baseline | 645 | 97.99 | 95.44 | 62.97 |
| 1st month | 637 | 99.22 | 89.56 | 63.70 |
| 3rd month | 642 | 98.91 | 86.50 | 62.70 |
| 6th month | 641 | 98.91 | 87.14 | 62.57 |
| 9th month | 641 | 99.22 | 95.91 | 62.57 |
| 12th month | 640 | 99.22 | 94.97 | 62.50 |
| 15th month | 640 | 98.44 | 92.19 | 62.50 |
Figure 2.Condom use during last sex with clients and regular partners.
Self-reported adherence.
| Visit | N | Pill taken daily in last month n (%) | Pill taken daily in last 7 days n(%) | Longest stretch of non-adherence in last month (>=7 d) |
|---|---|---|---|---|
| 1st month | 480 (75.35) | 573 (89.95) | 53 (8.32) | |
| 3rd month | 447 (69.63) | 568 (88.47) | 65 (10.12) | |
| 6th month | 575 (89.70) | 578 (90.17) | 2 (0.31) | |
| 9th month | 584 (91.11) | 584 (91.11) | 0 (0) | |
| 12th month | 623 (97.34) | 617 (96.41) | 0 (0) | |
| 15th month | 627 (97.97) | 629 (98.28) | 0 (0) |
Figure 3.Self-reported adherence.
Round 1 and round 2 comparison for tenofovir concentration.
| Round 1 | Round 2 | |
|---|---|---|
| Tenofovir Concentration (ng/mL) | n (%) | n(%) |
| No peak | 5 (5.88) | 3 (3.57) |
| Below 40 | 12 (14.12) | 5 (5.95) |
| 40 or above | 68 (80) | 76 (90.48) |
| Total | 85 | 84 |
Figure 4.Round 1 and round 2 comparison for tenofovir concentration.